Management of Essential Hypertension
Management of Essential Hypertension
复制标题
DOI：
10.1016/j.ccl.2016.12.005
复制
发表时间：
2017-05-01
影响因子：
2.4
通讯作者：
Nasser, Samar A.
中科院分区：
文献类型：
--
作者：
Ferdinand, Keith C.;Nasser, Samar A.
高血压的治疗是降低心血管发病率和死亡率的最关键的干预措施之一。美国的高血压患病率因种族/民族而异，与非西班牙裔白人相比，非洲裔美国人的患病率最高，总体上与非西班牙裔白人相比，在种族/少数民族中的控制率较低。治疗生活方式的改变是控制高血压的基础，但大多数高血压患者需要药物治疗，通常是多种药物联合使用。总体而言，推荐作为初始药物治疗的主要药物类别是噻嗪类利尿剂、钙通道阻滞剂和血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂。
The treatment of essential hypertension is one of the most critical interventions to decrease cardiovascular morbidity and mortality. The prevalence of hypertension in the US varies across race/ethnicity with African Americans having the highest prevalence and overall less control among racial/ethnic minorities compared with non-Hispanic whites. Therapeutic lifestyle modifications are the bedrock of essential hypertension control, but most patients with hypertension will require pharmacotherapy, usually with multiple medications often in combination. Overall, the principal drug classes recommended as initial pharmacotherapy are thiazide-type diuretics, calcium channel blockers, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.